Activated CHORD TM clinical trial sites in U.S., U.K. and Spain and commenced patient screening activities; anticipate dosing first patient in the Phase 1/2 clinical trial in the second half of 2023 Received FDA Breakthrough Therapy Designation for DB-020 for protection against hearing loss associated with cisplatin chemotherapy Announced on August 9 definitive agreement for Regeneron Pharmaceuticals to acquire Decibel... Read More

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 12:45 p.m. E.T in New York, NY.... Read More

BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois, June 2-6, 2023. The Company will present a poster summarizing... Read More

BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Barclays 2023 Gene Editing and Gene Therapy Summit on Wednesday, May 24, 2023 at 10:30... Read More

Initiated CHORD™, a global Phase 1/2 dose escalation clinical trial of lead gene therapy product candidate, DB-OTO Announced approval from the U.K. MHRA and Spanish AEMPS for CTAs for CHORD to expand the Phase 1/2 clinical trial to the U.K. and Spain in patients two years of age and younger Initiated manufacturing activities to support IND-enabling studies for our AAV.103 product candidate designed to restore hearing in... Read More

BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced approval of its Clinical Trial Application (CTA) by the Spanish Agency of Medicines and Medical Devices (AEMPS) to initiate a Phase 1/2 clinical trial in pediatric patients of DB-OTO,... Read More

BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25 th Annual Meeting, being held in Los Angeles, California May 16 – 20 th , 2023. The Company will deliver... Read More

Decibel intends to initiate a Phase 1/2 clinical trial of DB-OTO in patients with congenital hearing loss caused my mutations of the otoferlin gene in the first half of 2023 There are currently no approved pharmacologic treatment options for individuals with otoferlin-related hearing loss BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to... Read More

BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days on Monday, April... Read More

BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Matthew Kapusta to its Board of Directors. “We are pleased to welcome Matt to the Decibel Board. He is an accomplished life sciences executive who has played a key... Read More

Received clearance from US FDA for IND and from UK MHRA for CTA to initiate CHORD™, a global Phase 1/2 dose escalation clinical trial of DB-OTO in pediatric patients Plan to initiate the CHORD™ trial in the First Half of 2023 Presented key non-clinical data at the 46 th Annual ARO MidWinter Meeting supporting compelling safety profile of DB-OTO and preclinical data supporting selection of AAV.103 product candidate BOSTON,... Read More

BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will present a corporate overview at the SVB Securities Global Biopharma Conference being held virtually on Thursday, February 16,... Read More

BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present findings from its drug discovery and development programs at the 46 th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held... Read More

The CTA authorization for DB-OTO provides approval for the Company to expand its planned Phase 1/2 clinical trial to the U.K. in patients two years of age and younger One-time administration of DB-OTO has resulted in production of otoferlin protein and durable auditory brainstem responses to sound in a congenitally deaf rodent disease model Decibel intends to initiate the Phase 1/2 clinical trial of DB-OTO in the first half... Read More

Received FDA Clearance of IND Application for DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss Announced Submission of CTAs for DB-OTO in the United Kingdom and Spain Expect to Initiate a Phase 1/2 Clinical Trial of DB-OTO in the First Half of 2023 Plan to Identify AAV.103 Product Candidate in the Fourth Quarter of 2022 Decibel Therapeutics (Nasdaq: DBTX),... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the submission of Clinical Trial Applications (CTAs) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom and the Spanish Agency of Medicines and Medical Devices (AEMPS) for a Phase 1/2... Read More

The IND for DB-OTO provides clearance for the Company to initiate a pediatric Phase 1/2 clinical trial in the U.S. in children and infants, and is part of an international regulatory strategy for clinical development One-time administration of DB-OTO has resulted in production of otoferlin protein and durable auditory brainstem responses to sound in a congenitally deaf rodent disease model DB-OTO is Decibel’s second hearing... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Kevin F. McLaughlin to its Board of Directors. “We are pleased to welcome Kevin to the Decibel Board. He brings a wealth of biopharma experience, including guiding biotech companies through stages of... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022, at 10:00 a.m. ET in New York, NY. A live webcast of the... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial in pediatric patients of DB-OTO, a gene therapy product candidate designed to... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will be participating in the following upcoming investor conferences in September. Citi 17 th Annual BioPharma Conference: Rare disease panel on Wednesday, September 7, 2022... Read More

Announced positive data from interim analysis of Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy; data support continued development of DB-020 as a potential therapy to protect against hearing loss in patients receiving cisplatin chemotherapy for cancer Multiple milestones anticipated across gene therapy pipeline programs for congenital, monogenic hearing loss for remainder of 2022, with IND... Read More

87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear Data support continued development of DB-020 as a potential therapy to protect against hearing loss in patients receiving cisplatin chemotherapy for cancer Management will review results during a webcast today at 8:00 a.m. EDT Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that John Lee, chief development officer, and Lis Leiderman, M.D., MBA, chief financial officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 9:00 a.m. ET. A... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference. The fireside chat will be available for on-demand viewing starting... Read More

Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line results from interim analysis of Phase 1b trial of DB-020 for cisplatin-induced hearing loss and product candidate selection for AAV.103 program New preclinical data presented at the 45 th Annual Association for Research in Otolaryngology Conference (ARO) supporting DB-OTO and emphasizing platform focus on cell-selective... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25 th Annual Meeting, being held virtually and in Washington D.C. May 15-19, 2022. The Company will present on its lead investigational gene... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in the following upcoming virtual investor conferences in March. H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference : Dr. Reid will... Read More

Key anticipated catalysts in 2022 include submission of IND and/or CTA for DB-OTO and results from interim analysis from Phase 1b trial of DB-020 for cisplatin-induced hearing loss - Research term extended under strategic collaboration with Regeneron to discover and develop gene therapies for hearing loss - Announced AAV.104 gene therapy program for restoration of hearing in patients with stereocilin-related hearing loss -... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the 11 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 3:00 p.m. ET. A live webcast of... Read More

- Podium presentation at Association for Research in Otolaryngology Annual MidWinter Meeting highlighting DB-OTO dose-ranging studies with expression analysis, functional recovery and tolerability data - - Podium presentation and posters with new preclinical data supporting selective expression of GJB2 and STRC - BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright BioConnect Conference. The fireside chat will be available for on-demand viewing starting Monday,... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointments of Alison Finger, MBA and Saraswathy (“Sara”) Nochur, Ph.D. to its Board of Directors. “I am thrilled to welcome Alison and Sara to the Decibel Board. Both bring a wealth of biopharma experience that is very... Read More

Collaboration gene therapy product candidate, DB-OTO, on track to enter clinical testing in 2022; two additional gene therapy programs for congenital, monogenic forms of hearing loss in development under the collaboration Decibel to receive $10 million extension payment from Regeneron Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments... Read More

Received Orphan Drug and Rare Pediatric Disease designations for DB-OTO for the treatment of otoferlin-related congenital hearing loss On track for key 2022 milestones including submission of IND and/or CTA for DB-OTO and interim analysis of DB-020 Phase 1b trial for cisplatin-induced hearing loss Announces AAV.104 gene therapy program for restoration of hearing in patients with congenital hearing impairment due to recessive... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced its participation in the fifth annual Barclays Gene Editing & Gene Therapy Summit on Monday, November 15, 2021. Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at 3:30 pm ET and in... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 10:30 am ET. A live webcast of the fireside chat... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that findings from a study of noise-related inner ear damage conducted in collaboration with the University of Maryland School of Medicine (UMSOM) and the Karolinska Institute (KI) have been published in Cell Reports . The... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation and Rare Pediatric Disease Designation for the company’s lead gene therapy product candidate, DB-OTO, for the treatment of patients with... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the Company will participate in the following upcoming virtual investor conferences in September. Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in fireside chats at: H.C. Wainwright’s 23 rd... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Cynthia Hu, J.D., as Chief Legal Officer and Corporate Secretary. “Cynthia brings to Decibel more than 20 years of strategy, operations and legal experience, including 15 years in the life sciences industry.... Read More

Bolstered Board of Directors and Scientific Advisory Board with key appointments On track for anticipated 2022 milestones including submission of IND and/or CTA for DB-OTO and interim analysis of DB-020 Phase 1b trial for cisplatin-induced hearing loss Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of William (Bill) H. Carson, M.D., as Chairman of the Board of Directors. Dr. Carson, a board-certified psychiatrist, brings over 20 years of experience in the biopharmaceutical industry. He was most recently... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of leading experts in gene therapy, cochlear development and molecular genetics to its Scientific Advisory Board (SAB). “These additions to our SAB bring a deep understanding of the genetic roots of hearing... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will present at the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 7:00 am ET. A live webcast of the presentation may be accessed by... Read More

Established cGMP manufacturing and development agreement with Catalent for otoferlin dual-vector gene therapy, DB-OTO Successfully completed the second tranche of an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $165.3M in gross proceeds Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present two digital presentations at the American Society of Gene and Cell Therapy (ASGCT) 24 th Annual Meeting, to be held virtually May 11-14, 2021. The digital presentations will highlight Decibel’s innovative... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will present at the Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 4:30 pm ET. A live webcast of the presentation may be accessed by visiting... Read More

Successfully completed an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $220.1M in gross proceeds Established development and manufacturing agreement for otoferlin dual-vector gene therapy with Catalent Launched Amplify™ genetic testing program with Invitae for congenital hearing loss U.S. FDA Fast Track designation granted for DB-020 Presented 8 podium and poster presentations... Read More

Decibel Therapeutics (Nasdaq: DBTX) (“Decibel”), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it has been added to the Russell 2000 ® Index, as part of the index’s quarterly initial public offering (“IPO”) additions. Russell’s U.S. indexes are widely used by investment managers and institutional... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will present at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 9:10 a.m. ET. A live webcast of the presentation may be accessed by... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage company developing treatments to restore and improve hearing and balance, presented preclinical data supporting the company’s gene therapy product candidate, DB-OTO, a potential transformative treatment for individuals with hearing loss due to mutation of the otoferlin gene. These and other data were presented by the company at the 44 th Annual MidWinter Meeting of the... Read More

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present findings from its drug discovery and development programs at the 44 th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), which will be held virtually February 20–24, 2021.... Read More